January 11, 2018 / 9:22 PM / a year ago

BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

Jan 11 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY

* PUMA BIOTECHNOLOGY SAYS IT INTENDS TO MODIFY SUMMARY OF PRODUCT CHARACTERISTICS IN ITS MARKETING AUTHORIZATION APPLICATION FOR NERATINIB

* PUMA BIOTECHNOLOGY SAYS TO MODIFY SUMMARY FOR NERATINIB TO FURTHER REFINE INTENDED POPULATION TO PATIENTS AT A HIGH RISK OF DISEASE RECURRENCE Source text: (bit.ly/2D21ru9) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below